During the last three months, 6 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 1 | 0 | 1 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 1 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $95.67, a high estimate of $114.00, and a low estimate of $65.00. Surpassing the previous average price target of $56.00, the current average has increased by 70.84%.
Exploring Analyst Ratings: An In-Depth Overview
The analysis of recent analyst actions sheds...
Login or create a forever free account to read this news
Sign up/Log in